IL286838A - Btla-binding (cd272) antibodies for modulating immune response and treating disease - Google Patents

Btla-binding (cd272) antibodies for modulating immune response and treating disease

Info

Publication number
IL286838A
IL286838A IL286838A IL28683821A IL286838A IL 286838 A IL286838 A IL 286838A IL 286838 A IL286838 A IL 286838A IL 28683821 A IL28683821 A IL 28683821A IL 286838 A IL286838 A IL 286838A
Authority
IL
Israel
Prior art keywords
btla
antibodies
binding
immune response
treating diseases
Prior art date
Application number
IL286838A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lakepharma Inc
Trianni Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakepharma Inc, Trianni Inc filed Critical Lakepharma Inc
Publication of IL286838A publication Critical patent/IL286838A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL286838A 2019-04-01 2021-09-30 Btla-binding (cd272) antibodies for modulating immune response and treating disease IL286838A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827744P 2019-04-01 2019-04-01
PCT/US2020/025936 WO2020205849A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Publications (1)

Publication Number Publication Date
IL286838A true IL286838A (en) 2021-10-31

Family

ID=70296156

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286838A IL286838A (en) 2019-04-01 2021-09-30 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Country Status (8)

Country Link
US (2) US11384146B2 (enExample)
EP (1) EP3946622A1 (enExample)
JP (3) JP7596298B2 (enExample)
KR (1) KR20220047536A (enExample)
CN (2) CN114585416B (enExample)
CA (2) CA3302760A1 (enExample)
IL (1) IL286838A (enExample)
WO (1) WO2020205849A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
EP4469558A4 (en) * 2022-01-29 2026-02-25 Hifibio Inc Anti-BTLA antibodies and their uses in cancer treatment
AU2023212896A1 (en) * 2022-01-29 2024-08-22 Hifibio, Inc. Antibody against btla and uses thereof
US20230322929A1 (en) * 2022-04-12 2023-10-12 Shanghai Junshi Biosciences Co., Ltd. Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
EP4558226A1 (en) * 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025250861A1 (en) * 2024-05-31 2025-12-04 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-hcmv antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7153950B2 (en) 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
AR066170A1 (es) * 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
CA3013333A1 (en) * 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso

Also Published As

Publication number Publication date
US20230340123A1 (en) 2023-10-26
JP2022528005A (ja) 2022-06-07
CA3135836A1 (en) 2020-10-08
JP2026102772A (ja) 2026-06-23
JP7596298B2 (ja) 2024-12-09
WO2020205849A1 (en) 2020-10-08
EP3946622A1 (en) 2022-02-09
CN114585416B (zh) 2025-01-17
US20200325230A1 (en) 2020-10-15
CN119735682A (zh) 2025-04-01
CN114585416A (zh) 2022-06-03
KR20220047536A (ko) 2022-04-18
JP2025041629A (ja) 2025-03-26
JP7875929B2 (ja) 2026-06-18
US11384146B2 (en) 2022-07-12
CA3302760A1 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
DK3802598T3 (da) Dll3/cd3-bindingsproteiner til cancerbehandling
IL285943A (en) Dll3 targeting chimeric antigen receptors and binding agents
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
LT3638698T (lt) Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai
IL283939A (en) Antibodies binding to cd3
IL281787A (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
DK3802608T3 (da) Anti-cd3-antistoffer og anvendelser deraf
SG11202007578SA (en) Antibodies binding to gprc5d
EP3880247A4 (en) Bispecific antibodies for activation of immune cells
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
IL256871B (en) Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof
IL256760A (en) Human cd3 binding antibody
IL289829A (en) Immunomodulatory antibodies and methods of use thereof
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL280278A (en) Fcrn antibody compositions
PL4050034T3 (pl) Przeciwciała wiążące cd3
DK3615066T5 (da) Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
EP3576789C0 (en) BISPECIFIC ANTIBODIES AND FC OF HUMAN IGG1 MONOMERS
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
HK1218550A1 (zh) 常見輕鏈小鼠
CA3302760A1 (en) Btla-binding (cd272) antibodies for modulating immune response and treating disease
IL284807A (en) Antibodies specific to human nectin-2